- Home
- QCRH vs SANA Comparison
QCRH vs SANA Comparison
Compare QCRH & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- SANA
- Stock Information
- Founded
- QCRH 1993
- SANA 2018
- Country
- QCRH United States
- SANA United States
- Employees
- QCRH N/A
- SANA N/A
- Industry
- QCRH Major Banks
- SANA Medicinal Chemicals and Botanical Products
- Sector
- QCRH Finance
- SANA Health Care
- Exchange
- QCRH Nasdaq
- SANA Nasdaq
- Market Cap
- QCRH 1.1B
- SANA 983.4M
- IPO Year
- QCRH 1993
- SANA 2021
- Fundamental
- Price
- QCRH $76.31
- SANA $4.18
- Analyst Decision
- QCRH Buy
- SANA Strong Buy
- Analyst Count
- QCRH 4
- SANA 7
- Target Price
- QCRH $90.00
- SANA $8.00
- AVG Volume (30 Days)
- QCRH 111.5K
- SANA 6.8M
- Earning Date
- QCRH 10-22-2025
- SANA 11-11-2025
- Dividend Yield
- QCRH 0.32%
- SANA N/A
- EPS Growth
- QCRH 3.93
- SANA N/A
- EPS
- QCRH 7.15
- SANA N/A
- Revenue
- QCRH $336,623,000.00
- SANA N/A
- Revenue This Year
- QCRH N/A
- SANA N/A
- Revenue Next Year
- QCRH $18.11
- SANA N/A
- P/E Ratio
- QCRH $10.59
- SANA N/A
- Revenue Growth
- QCRH N/A
- SANA N/A
- 52 Week Low
- QCRH $60.83
- SANA $1.26
- 52 Week High
- QCRH $96.08
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- QCRH 55.79
- SANA 42.04
- Support Level
- QCRH $71.69
- SANA $5.12
- Resistance Level
- QCRH $77.85
- SANA $5.00
- Average True Range (ATR)
- QCRH 2.48
- SANA 0.49
- MACD
- QCRH 0.52
- SANA -0.18
- Stochastic Oscillator
- QCRH 82.49
- SANA 0.00
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.